---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001228"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:29:20.112148+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports positive Phase 1 data for NPM-115 implant and prioritizes semaglutide implant NPM-139

## Summary
- Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.
- LIBERATE-1 Phase 1 study of NPM-115 (exenatide implant) met primary safety and PK objectives; no serious adverse events.
- Preclinical data for NPM-139 (semaglutide implant) showed ~20% weight loss maintained over 231 days from a single implant.
- Vivani prioritizes NPM-139 for clinical development, with IND submission planned and clinical start expected in 2026.
- Semaglutide products (Ozempic, Wegovy, Rybelsus) generated over $29B in 2024 sales, supporting prioritization.

## SEC filing metadata
- accession: 0001753926-25-001228
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001228/0001753926-25-001228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001228/vani-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001228
- JSON: https://secwatch.observer/filing/0001753926-25-001228.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.